Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 2,000 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $29.70, for a total value of $59,400.00. Following the transaction, the chief financial officer directly owned 234,527 shares in the company, valued at $6,965,451.90. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, September 22nd, Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15.
• On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.82, for a total transaction of $354,860.66.
• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total transaction of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total transaction of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87.

Hims & Hers Health Stock Down 1.2%

NYSE HIMS traded down $0.34 during trading hours on Friday, hitting $28.96. The company’s stock had a trading volume of 10,052,970 shares, compared to its average volume of 23,671,156. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30. The company has a market capitalization of $6.76 billion, a PE ratio of -45.97 and a beta of 2.44. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The company’s 50-day simple moving average is $29.27 and its two-hundred day simple moving average is $28.24.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.17 earnings per share. Research analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in HIMS. MassMutual Private Wealth & Trust FSB boosted its stake in Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after buying an additional 319 shares in the last quarter. Sigma Planning Corp raised its stake in shares of Hims & Hers Health by 1.5% during the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after acquiring an additional 388 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after acquiring an additional 665 shares during the last quarter. BIP Wealth LLC lifted its holdings in shares of Hims & Hers Health by 6.0% in the 1st quarter. BIP Wealth LLC now owns 16,278 shares of the company’s stock worth $338,000 after acquiring an additional 915 shares during the last quarter. Finally, Winnow Wealth LLC boosted its stake in shares of Hims & Hers Health by 4.6% in the 4th quarter. Winnow Wealth LLC now owns 22,282 shares of the company’s stock valued at $735,000 after purchasing an additional 980 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on HIMS. Barclays reduced their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Friday, August 21st. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Truist Financial lifted their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research report on Monday, August 24th. Bank of America upped their target price on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Finally, Morgan Stanley increased their price target on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $32.43.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia appointed chief medical officers in the United Kingdom and Australia, strengthening local clinical leadership as the company expands internationally. Hims & Hers Names Chief Medical Officers in the UK and Australia
• Neutral Sentiment: Multiple law firms, including Rosen, Kaplan Fox, SBS and Robbins Geller, reminded investors that purchasers of HIMS securities between August 4, 2025, and July 29, 2026, may seek appointment as lead plaintiff by November 2, 2026. These announcements are largely procedural and do not represent new claims by themselves. Rosen Securities Class Action Deadline Notice
• Negative Sentiment: Hims & Hers is the subject of a securities class action alleging that the company and certain executives made material misstatements or omissions, including regarding allegedly deceptive and unlawful privacy practices. The case reportedly follows an FTC complaint alleging serious business misconduct. The allegations have not been proven, but the litigation could create legal costs, potential damages and additional regulatory or reputational pressure. Hims & Hers Securities Class Action Following FTC Complaint
• Negative Sentiment: Recent reports noted that HIMS declined during a session in which the overall market rose, suggesting investor sentiment remains pressured by the FTC-related controversy and lawsuit headlines. Continued coverage from numerous plaintiff firms may keep volatility elevated while investors await developments in the case. HIMS Stock Slides as Market Rises

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.